Mazdutide and survodutide are both GLP-1/glucagon dual agonists given as once-weekly subcutaneous injections, so they share a receptor class rather than differing on it. The real distinctions are their development programs, geography, and trial dosing: mazdutide has been developed mainly in China, while survodutide is being developed by Boehringer Ingelheim and studied in obesity and MASH. Neither is FDA-approved, and cross-trial efficacy comparisons are not reliable.
Reviewed for accuracy · Last reviewed July 8, 2026Unlike the triple-agonist comparisons, these two share a receptor class: both pair GLP-1 with glucagon, and neither adds GIP. So the difference is not mechanism at the receptor level but development program, geography, and the doses each trial studied.
Mazdutide's human data comes largely from Chinese Phase 2 and Phase 3 trials (including GLORY-1 and GLORY-2), and it holds a 2025 China NMPA approval but no FDA or EMA approval. Survodutide is investigational everywhere, with Phase 2 data in obesity and in MASH with fibrosis and Phase 3 obesity trials ongoing. Their trials used different dose ranges and endpoints, so comparing reported weight-loss numbers across them would not be a fair head-to-head.
Both reported predominantly gastrointestinal side effects (nausea, vomiting, diarrhea) that were generally dose-related and concentrated during escalation. None of this is medical advice, and independently sourced vials of either carry no guarantee of the testing a regulated product would receive.
This page is an independent educational reference and is not medical advice, and does not indicate any approval status for any use. Talk to a doctor before starting any compound.